Key regions: France, India, United Kingdom, South Korea, Japan
The demand for Multiple Sclerosis Drugs in Cambodia has been increasing steadily over the past few years.
Customer preferences: Cambodia is a developing country with a growing middle class population. As the population ages, the incidence of Multiple Sclerosis is expected to increase. The majority of Multiple Sclerosis patients in Cambodia are women, and they are more likely to seek medical treatment than men. Patients in Cambodia prefer to use generic drugs, which are more affordable than branded drugs.
Trends in the market: The Multiple Sclerosis Drugs market in Cambodia is expected to grow at a steady pace in the coming years. The market is being driven by an increase in the number of Multiple Sclerosis patients, rising healthcare expenditure, and the availability of generic drugs. The demand for drugs that can slow down the progression of the disease is expected to increase.
Local special circumstances: Cambodia has a limited healthcare infrastructure, and the availability of drugs is often limited in rural areas. The government is taking steps to improve access to healthcare in rural areas, which is expected to increase the demand for Multiple Sclerosis Drugs. The lack of awareness about Multiple Sclerosis among the general population is also a challenge for the market.
Underlying macroeconomic factors: Cambodia is one of the fastest-growing economies in Southeast Asia, with a growing middle class population. The country has a young population, which is expected to drive economic growth in the coming years. The government is investing in infrastructure development, which is expected to improve access to healthcare in rural areas. The pharmaceutical industry in Cambodia is still in its nascent stage, but the government is taking steps to promote the industry. The country has a favorable business environment, which is expected to attract more foreign investment in the coming years.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
